Purchase Order 75N93024P01096
Award Date 9/4/24
Potential Completion Date 11/1/24
Potential Value $3.7K
Federal Agency
Ultimate Awardee
Not listed NAICS Category
PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Not Competed under SAP
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Piscataway, NJ 08854, USA
Solicitation Procedures
Simplified Acquisition
Number Of Offers Received
1
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The National Institute of Allergy and Infectious Diseases awarded a $96,595 firm fixed-price purchase order to Genscript USA Inc. on September 20, 2024, for monoclonal antibodies and plasmids services under the FY26 Urgent and Directed Obligation Initiative. The contract is not designated as a set-aside award and carries an ultimate completion date of September 19, 2025. Performance will be conducted at Genscript's facility in Piscataway, New Jersey, where the company maintains its...
- <p>The National Institute of Allergy and Infectious Diseases awarded a purchase order to Genscript USA Inc. for antibody gene synthesis and production, valued at $16,974.27, on August 26, 2020. The order was firm fixed price with an ultimate completion date of February 6, 2021. Work was performed at Genscript's facility in Piscataway, New Jersey.</p>
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $156,442.59 firm fixed-price purchase order to Genscript USA Inc. for gene synthesis and protein production services under the FY26 UDO Initiative (AMBIS #2136137). The contract was awarded on August 31, 2022, with an ultimate completion date of September 1, 2023, and represents work to be performed at Genscript's facility in Piscataway, New Jersey. This contract was not designated as a set-aside award and resulted...
- The National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) awarded a firm fixed-price purchase order contract worth $66,835.54 to Genscript USA Inc., a biotechnology company in Piscataway, New Jersey. The contract is for the custom synthesis of genes and antibodies to support NIAID's biomedical research and public health initiatives. The contract was awarded on a sole-source basis under the authority of FAR 13.106-1 due to Genscript being the...
- <p>The National Institute of Allergy and Infectious Diseases awarded a purchase order to Genscript USA Inc. for customized DNA and monoclonal antibody production, valued at $49,653.58, on August 6, 2020. Performance is located in Piscataway, New Jersey. The order is firm fixed price with an ultimate completion date of September 5, 2020.</p>
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $249,243.54 firm fixed price purchase order to Genscript USA Inc. on August 27, 2023, for gene production and protein expression services. The contract, which was completed on August 26, 2024, encompasses gene synthesis, cloning, plasmid preparation, protein expression, and purification services to support NIAID's research initiatives. This was a sole source negotiated contract with no set-aside designation, awarded...
- <p>The National Institute of Allergy and Infectious Diseases awarded a purchase order to Genscript USA Inc. for $70,395.88 on June 26, 2019, for antibodies (AMBIS #1962008) under firm fixed price, with completion targeted for September 30, 2019. Work is performed in Piscataway, New Jersey. The order originated from a pre-solicitation opportunity posted June 13, 2019, with a due date of June 24, 2019. No small business set-aside applied.</p>
- The Department of Health and Human Services' National Institutes of Health National Institute of Allergy and Infectious Diseases awarded a $264,030.54 firm fixed price purchase order to Genscript USA Inc., a for-profit biotechnology company, for antibody expression and plasmid preparation services in support of COVID-19 research. The contract, which has a completion date of February 24, 2022, does not have a set-aside designation. Genscript, which has provided similar products and services to...
- <p>The National Institute of Allergy and Infectious Diseases awarded a purchase order to Genscript USA Inc. for customized monoclonal antibody on June 27, 2018, with a ceiling value of $30,289.88 and firm fixed pricing. Performance is located in Piscataway, New Jersey, with an ultimate completion date of July 10, 2018. No small business set-aside was used.</p>
- The National Institute of Allergy and Infectious Diseases awarded a purchase order to Genscript USA Inc. on August 23, 2023, for DNA services valued at $34,502.16. The order covers gene synthesis, VectorArk cloning, and express plasmid preparation. Performance occurs in Piscataway, New Jersey. The services support development of peptide and protein immunogens and DNA constructs for MPER-scaffolded proteins used in vaccine research against HIV, influenza, Ebola, Marburg, and other infectious...